Key points are not available for this paper at this time.
Merck KGaA will invest 326 million in a bioprocessing complex in Daejeon, South Korea, marking its largest investment in the Asia-Pacific region. The 43, 000 m 2 site will contain production facilities, a distribution center, and an automated warehouse. The facility will provide biotech products and services such as dry powder cell culture media, process liquids, sterile sampling systems, and small-scale manufacturing to support drug industry customers, the German firm says.
Aayushi Pratap (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: